Carzenide

Carzenide (4-Sulfamoylbenzoic acid) is the major circulating metabolite of Mafenide (HY-B0614) in plasma. Carzenide is a strong CAII competitive inhibitor. Carzenide can be used in the research of epilepsy and cervical cancer[1][2][3].

Product Specifications

CAS Number

[138-41-0]

Product Name Alternative

4-Sulfamoylbenzoic acid

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Carbonic Anhydrase; Drug Metabolite

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Carzenide.html

Purity

99.86

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)C1=CC=C(S(=O)(N)=O)C=C1

Molecular Formula

C7H7NO4S

Molecular Weight

201.20

Precautions

H302, H315, H319, H335

References & Citations

[1]Weisdorf DJ, et al. Mafenide (Sulfamylon) inhibits plasmin fibrinolytic activity. Thromb Haemost. 1988 Jun 16;59 (3) :440-4. PMID: 2973151. |[2]Zhang F, et al. Imaging of Carbonic Anhydrase Level in Epilepsy with an Environment-Sensitive Fluorescent Probe. Anal Chem. 2023 Oct 10;95 (40) :14833-14841.|[3]Abo-Ashour MF, et al. Novel synthesized SLC-0111 thiazole and thiadiazole analogues: Determination of their carbonic anhydrase inhibitory activity and molecular modeling studies. Bioorg Chem. 2019 Jun;87:794-802.